• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nuwellis Inc.

    8/30/24 4:11:06 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NUWE alert in real time by email
    SC 13G 1 ea021310701-13gintra_nuwe.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.    )*

     

    Nuwellis, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    67113Y405

     

    (CUSIP Number)

     

    August 23, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 7

     

    CUSIP No. 67113Y405

     

    1. Names of Reporting Persons.

    Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    98,050
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    98,050
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    98,050 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 2 of 7

     

    CUSIP No. 67113Y405

     

    1. Names of Reporting Persons.

    Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b) ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    98,050
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    98,050
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    98,050 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 3 of 7

     

    CUSIP No. 67113Y405

     

    1. Names of Reporting Persons.

    Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    Delaware
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    98,050
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    98,050
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    98,050 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    OO

     

    Page 4 of 7

     

    Item 1.

     

    (a) Name of Issuer

     

    Nuwellis, Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    12988 Valley View Road

    Eden Prairie, Minnesota 55344

     

    Item 2.

     

    (a) Name of Person Filing

     

    (b) Address of Principal Business Office or, if none, Residence

     

    (c) Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d) Title of Class of Securities

     

    Common stock, par value $0.0001 per share, of the Issuer (the “Common Stock”).

     

    (e) CUSIP Number

     

    67113Y405

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on August 23 2024 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 26, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 81,301 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 5.6% of the Common Stock, based on (1) 1,383,539 shares of Common Stock outstanding prior to the execution of the SPA as reported to the Reporting Persons by the Issuer, plus (2) 81,301 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 81,301 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”) because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (II) 847 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 250,994 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (IV) 103,774 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 518,217 shares of Common Stock.

    Page 5 of 7

     

    (ii) As of the close of business on August 30, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 98,050 shares of Common Stock, which consisted of (i) 81,301 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (ii) 847 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 and (iii) 15,902 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 1,383,539 shares of Common Stock outstanding prior to the execution of the SPA as reported to the Reporting Persons by the Issuer, plus (2) 483,351 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 81,301 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (4) 847 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 and (5) 15,902 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3. The foregoing excludes (I) 235,092 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (II) 103,774 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 436,916 shares of Common Stock.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote:            0             .

     

    (ii)Shared power to vote or to direct the vote:            98,050             .

     

    (iii)Sole power to dispose or to direct the disposition of            0            .

     

    (iv)Shared power to dispose or to direct the disposition of            98,050            .

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 6 of 7

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 30, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 7 of 7

     

    Get the next $NUWE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUWE

    DatePrice TargetRatingAnalyst
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®

    ULTRA-Peds Registry, the largest multi-center dataset of its kind, shows Aquadex therapy was well-tolerated in critically ill children, a population with extremely limited treatment options Results highlight life-threatening gaps in pediatric care and underscore Nuwellis' commitment to pediatric innovation and integrated cardio-renal care MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced findings from the ULTRA-Peds registry, a multi-center observational study examining the re

    9/30/25 8:45:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration

    EDEN PRAIRIE, Minn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021 on September 16, 2025, based on Application No. 18/298,860. The patent relates to the use of one or more hemolysis sensors with extracorporeal blood filtration systems—such as ultrafiltration therapy and continuous renal replacement therapy (CRRT)—to help detect and localize red blood cell destruction occurring within or around the circuit. The intellectual property supports Nuwellis' pediatric device, Vivian, in development and future platform innovation. Why hemolysis matters Hemolys

    9/18/25 9:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. Participates in a Virtual Investor "What This Means" Segment

    Watch the "What This Means" segment here MINNEAPOLIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it participated in a Virtual Investor "What This Means" segment.  For the segment, Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company's recent news release announcing that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT). The NIH-supported program will accelerate Vivian™, Nu

    9/17/25 10:16:49 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Nuwellis with a new price target

    ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

    7/29/24 7:42:07 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Leadership Update

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    10/8/25 5:10:35 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Other Events

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    9/30/25 8:55:19 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Other Events

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    9/18/25 9:18:17 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Erb John L

    4 - Nuwellis, Inc. (0001506492) (Issuer)

    7/1/25 8:30:33 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CEO and President Erb John L converted options into 1,100,022 shares (SEC Form 4)

    4 - Nuwellis, Inc. (0001506492) (Issuer)

    6/11/25 8:43:36 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Mcdonald David

    4 - Nuwellis, Inc. (0001506492) (Issuer)

    5/21/25 4:59:22 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints John Erb as Chief Executive Officer

    WHOWHATWHEREWHENHOWJohn ErbAppointed as Chief Executive Officer (no longer serving in an interim capacity)Nuwellis HeadquartersEffective June 27, 2025Appointment confirmed by the Board of Directors following his interim leadership MINNEAPOLIS, July 02, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to advancing solutions in fluid management, today announced the appointment of John Erb as its Chief Executive Officer. Erb, who has served as interim CEO since February 2025, will continue to lead the company with a focus on strategic clarity, operational discipline, and sustainable growth. This marks Erb's return to the CEO role at Nuwellis, havi

    7/2/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

    MINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of Interim President and Chief Executive Officer and assumed all of the duties formerly performed by Mr. Jaramillo. Nuwellis intends to retain an executive search firm to assist in identifying a permanent CEO. Mr. Erb, stated, "Nestor has been with the company for nearly si

    2/24/25 4:05:00 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Board of Directors Transition

    MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. "With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board. Dave's significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives. In turn, our board will benefit from perspectives gained from Archelle's healthcare policy, clinical, and patient education experience

    11/1/23 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Financials

    Live finance-specific insights

    View All

    Nuwellis Postpones Second Quarter 2025 Earnings Release and Conference Call to August 14, 2025

    MINNEAPOLIS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on fluid management, today announced that it will postpone its 2025 second quarter earnings release and conference call, originally scheduled for August 12, 2025. The Company requires additional time to complete its valuations and for its audit firm to complete its related audit procedures. There are no current disagreements with Baker Tilly US, LLP, the Company's auditor. The Company expects to host a conference call and webcast at 9:00 AM ET on August 14, 2025 to discuss its financial results and provide a general business update. To access the live webcast, please visit the

    8/6/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025

    MINNEAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the second quarter 2025 on August 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-245-3047 (U.S) or 1-203-518-9765 (international) and using the conference ID: NUWEQ2. A

    7/22/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

    MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em

    5/13/25 7:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    8/30/24 4:11:06 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    8/2/24 4:12:11 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    5/6/24 4:01:02 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care